课题基金 / 基金详情

Regulation of ENaC Transcription

Regulation of ENaC Transcription
ENaC 转录的调控
批准号:
7081856
负责人:
BRUCE C. KONE
金额:
$36.25万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-04 至 2010-03-31

项目摘要

项目成果

BRUCE C. KONE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究的主要目标是确定肾脏上皮Na+通道a-亚基(ENaCa)转录控制的分子机制。钠。是一种多亚基蛋白,在控制上皮Na+转运、血压和对高醛固酮增多症的反应中起主要作用。ENaCa亚基是由收集管中的醛固酮诱导的,似乎是ENaC活性在该段的限速。尽管它很重要,但控制ENaCa转录和醛固酮诱导ENaCa的机制尚不完全明确。我们描述了一种新的组蛋白甲基转移酶,端粒沉默干扰物(Dot1),并表明它与AF9a相互作用,在小鼠ENaCa基因的5'侧区形成染色质相关抑制复合物。通过sgk1介导的AF9a磷酸化,醛固酮破坏该复合物,减轻对ENaCa的抑制并激活其转录,而不依赖于矿物皮质激素受体的作用。我们现在建议使用定量染色质免疫沉淀测定和启动子-报告子瞬时转染测定来跟踪特定转录因子和协同调节蛋白与ENaCa启动子处AF9a-Dot1复合物的关联,以确定结合模式,以测试有关这些因子之间相互作用的假设。并监测在基础条件下和醛固酮作用下与ENaCa基因转录激活相关的共价组蛋白修饰的变化。确定的核蛋白改变反式ENaCa启动子的能力将在共表达和RNA干扰实验中进行测试。在转基因小鼠中的研究将测试所鉴定的候选AF9a调控元件是否对内源性ENaCa基因的反应忠实复制至关重要。目的1将验证AF9a是一种转录抑制因子的假设,该转录抑制因子结合ENaCa的5'侧区,并使特定的辅抑制因子和染色质重塑蛋白有序地募集到ENaCa启动子上。Aim 2将验证AF9a、Dot1、SIRT1、Rad6等共调节蛋白促进组蛋白超甲基化和去乙酰化以及ENaCa基础抑制的假设。目的3将验证醛固酮和SGK1促进AF9a元件位点上协同调节蛋白的顺序和组合募集和释放的假设,从而决定ENaCa基因的激活。这些研究将使我们能够构建一个新的、动态的ENaCa基因在肾脏中的调控网络,并为复杂基因的转录控制和矿化皮质激素的分子作用提供重要的见解。拟议的研究还将定义SGK1、Dot1和AF9a的新功能模式,这些模式可能更广泛地适用于其他靶蛋白和一般的基因调控。
英文摘要
DESCRIPTION (provided by applicant): The broad goal of this research is to identify the molecular mechanisms underlying transcriptional control of the epithelial Na+ channel a-subunit (ENaCa) in kidney. ENaC .is a multi-subunit protein that plays a major role in control of epithelial Na+ transport, blood pressure, and the response to hyperaldosteronism. The ENaCa subunit is induced by aldosterone in the collecting duct, and appears to be rate-limiting for ENaC activity in this segment. Despite its importance, the mechanisms controlling ENaCa transcription and its induction by aldosterone are incompletely defined. We have characterized a novel histone methyltransferase, disrupter of telomeric silencing (Dot1), and show that it interacts with AF9a to form a chromatin-associated represser complex in the 5'-flanking region of the mouse ENaCa gene. Through SGK1-mediated phosphorylation of AF9a, aldosterone disrupts the complex, relieving the repression on the ENaCa and activating its transcription, independent of actions of the mineralocorticoid receptor. We now propose to use quantitative chromatin immunoprecipitation assays and promoter-reporter transient transfection assays to follow association of specific transcription factors and coregulatory proteins with the AF9a-Dot1 complex at the ENaCa promoter, to define patterns of binding, to test hypotheses regarding interactions among these factors, and to monitor changes in covalent histone modifications associated with transcriptional activation of the ENaCa gene under basal conditions and in response to aldosterone. The ability of defined nuclear proteins to alter the ENaCa promoter in trans will be tested in coexpression and RNA interference experiments. Studies in transgenic mice will test whether the candidate AF9a regulatory element identified is critical for faithful replication of the responses of the endogenous ENaCa gene. Aim 1 will test the hypothesis that AF9a is a transcriptional represser that binds the 5' flanking region of ENaCa and nucleates the ordered recruitment of specific corepressors and chromatin remodeling proteins to the ENaCa promoter. Aim 2 will test the hypothesis that AF9a, Dot1, SIRT1, Rad6 and other coregulator proteins promote histone hypermethylation and deacetylation and basal repression of ENaCa. Aim 3 will test the hypothesis that aldosterone and SGK1 promote sequential and combinatorial recruitment and dismissal of coregulatory proteins at the AF9a element locus, dictating ENaCa gene activation. These studies will allow us to construct a novel, dynamic regulatory network to the overall model of ENaCa gene regulation in kidney, and to provide important insights into transcriptional control of complex genes and the molecular actions of mineralocorticoids. The proposed studies will also define new modes of function for SGK1, Dot1, and AF9a that may be more broadly applicable to other target proteins and to gene regulation in general.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of ENaC Transcription
  • 批准号:
    7456744
  • 项目类别:
  • 资助金额:
    $29.16万
  • 财政年份:
    2006
  • 负责人:
    BRUCE C. KONE
  • 依托单位:
Regulation of ENaC Transcription
Regulation of ENaC Transcription
  • 批准号:
    7616173
  • 项目类别:
  • 资助金额:
    $6.8万
  • 财政年份:
    2006
  • 负责人:
    BRUCE C. KONE
  • 依托单位:
Regulation of ENaC Transcription
国内基金
海外基金
海马神经元胆固醇代谢重编程致染色质组蛋白乙酰化水平降低介导老年小鼠术后认知功能障碍
  • 批准号:
    82371192
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    田婕
  • 依托单位:
HK2乳酰化修饰介导巨噬细胞功能障碍在脓毒症中的作用及机制
  • 批准号:
    82372160
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈峰
  • 依托单位:
组蛋白乙酰化修饰ATG13激活自噬在牵张应力介导骨缝Gli1+干细胞成骨中的机制研究
  • 批准号:
    82370988
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    经典
  • 依托单位: